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Microglia activated in response to brain injury release neurotoxic factors including nitric oxide (NO) and proinﬂammatory
cytokines such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β). Ketamine, an anesthetic induction agent, is
generally reserved for use in patients with severe hypotension or respiratory depression. In this study, we found that ketamine (100
and 250μM) concentration-dependently inhibited lipopolysaccharide (LPS)-induced NO and IL-1β release in primary cultured
microglia. However, ketamine (100 and 250μM) did not signiﬁcantly inhibit the LPS-induced TNF-α production in microglia,
except at the higher concentration (500μM). Further study of the molecular mechanisms revealed that ketamine markedly
inhibited extracellular signal-regulated kinase (ERK1/2) phosphorylation but not c-Jun N-terminal kinase or p38 mitogen-
activated protein kinase stimulated by LPS in microglia. These results suggest that microglial inactivation by ketamine is at least
partially due to inhibition of ERK1/2 phosphorylation.
Copyright © 2009 Yi Chang et al. This is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
M i c r o g l i aa r eat y p eo fn e u r o g l i at h a ts u p p o r t ,n u r t u r e ,
and protect neurons which maintain homeostasis of the
ﬂuid that bathes neurons [1]. It is an innate immune
componentofthecentralnervoussystem(CNS)parenchyma
[2]. Under physiological conditions, residential microglia are
quiescent and scattered throughout the CNS. Occasionally,
microglia are moderately activated to play the classic role
as scavengers for maintaining and restoring the CNS.
Activated microglia release proinﬂammatory cytokines such
as interleukin-1β (IL-1β)a n dt u m o rn e c r o s i sf a c t o r - α (TNF-
α) to induce inﬂammatory responses [3]. Furthermore, they
also release neurotoxins like reactive oxygen species (ROS)
and nitric oxide (NO) [4], which amplify the inﬂammatory
responses and cause neuronal damage in the CNS. Sustained
overactivation of microglia is found in many neurode-
generative diseases such as multiple sclerosis, Alzheimer’s
disease, Parkinson’s disease, HIV-associated dementia, and
ischemia/reperfusion brain injury [5, 6].
Endotoxins are high-molecular-weight complexes of
lipopolysaccharide (LPS) that are major components of
the outer membranes of the cell walls of gram-negative
bacteria[7].Themostseveresepticmicrovascularinﬂamma-
tory responses, however, are caused by gram-negative bac-
teriemia, and these responses can be produced by an injec-
tion of LPS. Endothelial injury, activation of the coagulation
cascade, platelet aggregation, and thrombocytopenia have all
been shown to contribute to vascular ﬁbrin deposition in
LPS-induced septic shock [7–9]. LPS also triggers a series of
inﬂammatory reactions in microglia. LPS is known to induce
NO and TNF-α production in microglia through various
extracellular signal-regulated kinase (ERK), p38 mitogen-
activated protein kinase (p38 MAPK), and c-Jun N-terminal
kinase (JNK) pathways [10, 11].2 Mediators of Inﬂammation
Ketamine, an anesthetic induction agent, is generally
reserved for use in patients with severe hypotension or
respiratory depression [12]. As we described previously,
ketamine (200 and 350μM) signiﬁcantly inhibited platelet
activation stimulated by collagen [13]. On the other hand,
ketamine has been reported to exert anti-inﬂammatory
eﬀects on macrophages and leucocytes in in vitro and in
vivo studies [14–16]. Shibakawa et al. [17] also reported that
ketamine (300∼1000μM) signiﬁcantly inhibited some of
the inﬂammatory responses in microglial cells stimulated by
LPS. However, the detailed mechanisms underlying the anti-
inﬂammatory eﬀects of ketamine in microglia stimulated
by LPS still have not been completely resolved yet. We
therefore further examined the eﬀect of ketamine in LPS-
induced microglial activation in primary cultures from rats
and utilized the ﬁndings to further characterize the anti-
inﬂammatory eﬀects of ketamine.
2.MaterialsandMethods
2.1. Materials. Ketamine, LPS (Escherichia coli,s e r o t y p e
0127: B8), and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-
tetrazolium bromide (MTT) were purchased from Sigma
(St. Louis, Mo, USA); RPMI-1640 medium, fetal bovine
serum (FBS), trypsin (0.25%), L-glutamine, and peni-
cillin/streptomycin were from GibcoBRL (Gaithersburg,
Md, USA); deoxyribonuclease type I (DNase I) was
from Roche (Indianapolis, Ind, USA); anti-ERK1/2, anti-
phospho-ERK1/2 (Thr202/Tyr204), anti-JNK1/2, anti-p38
MAPK, and anti-phospho-JNK1/2 (Thr183/Tyr185)m o n o -
clonal antibodies (mAbs) were from Cell Signaling (Beverly,
Mass, USA); the anti-phospho-p38 MAPK (Ser182)m A bw a s
from Santa Cruz (Santa Cruz, Calif, USA); the horseradish
peroxidase-conjugated secondary antibody was from Amer-
sham (Buckinghamshire, UK); and the IL-1β and TNF-α
enzyme immunoassay (EIA) kits were from R&D Systems
(Minneapolis, Minn, USA).
2.2. Cell Cultivation. Wistar rats (7 days old; from the
Experimental Animal Center, College of Medic ine, National
Taiwan University) were used in this study. All animal
experiments and care were performed according to the
Guide for the Care and Use of Laboratory Animals (National
Academy Press, Washington, DC, 1996). Wistar rats were
deeply anesthetized with ether and transcardially perfused
with normal saline until the lungs and liver were clear of
blood. After perfusion, the brain was removed and kept
in RPMI-1640 medium. After dissecting the meninges, the
brain tissue was minced in ice-cold RPMI-1640 and treated
with trypsin (0.25%) and deoxyribonuclease (10mgmL
−1)
in RPMI-1640 for 2 hours at 37◦C. Treated tissues were
further minced in 10% FBS and centrifuged at 1000rpm for
10 minutes. The tissue pellet was resuspended in RPMI-1640
and then seeded in 75cm2 ﬂasks at 37◦C (95% O2 and 5%
CO2).
Microglia were harvested from ﬂasks of mixed glial
cultures after shaking for 2 hours. Cells were collected by
centrifugation and then seeded at 5 × 105 cells mL
−1.A f t e r
incubation for 1 hour at 37◦C, nonadherent or weakly
adherent cells were removed by gentle shaking and washed
out.CellswerefurtherculturedinRPMI-1640supplemented
with 10% FBS for 1 day. Approximately 2 × 106 cells were
obtained per brain used [18]. To determine the purity of the
microglia, an immunocytochemical analysis was carried out
using a microglial-speciﬁc OX-42 antibody. These primary
culturedcellswere>95%OX-42-positiveindicatingthatthey
were composed of microglia.
2.3. Cell Viability. Microglial viability after 24 hours of
continuous exposure to diﬀerent concentrations of LPS
(1∼200ngmL
−1) and ketamine (100∼500μM) was mea-
sured with a colorimetric assay based on the ability of
mitochondria in viable cells to reduce the MTT as previously
described [19]. The percentage of cell viability was calculated
as the absorbance of treated cells/control cells × 100%.
2.4. Determination of Nitrite Concentration. To determine
NO production from microglia, nitrite (a stable oxidative
end product of NO) accumulation in the media of microglia
was measured using a colorimetric method [18], with minor
modiﬁcations. Brieﬂy, 100 μL of supernatant was incubated
with an equal volume of Griess reagent (1% sulfanilamide
and 0.1% naphthyl-ethylenediamine dihydrocholoride in
2.5% phosphoric acid). After a 30-minute incubation at
room temperature, the optical absorbance at 550nm was
measured with a microplate reader. Nitrite concentrations
were calculated by regression with standard solutions of
sodium nitrite prepared in the same culture medium [18].
2.5. Enzyme-Linked Immunosorbent Assay (ELISA) of IL-
1β and TNF-α. For determination of IL-1β and TNF-α
production from microglia, microglia (5 × 105 cells mL
−1)
were plated onto 24-well culture plates for 24 hours. Cells
were pretreated with various concentrations of ketamine
(100∼500μM) or an isovolumetric PBS buﬀer for 30
minutes and then treated with LPS (100ngmL
−1) for the
indicated times (1∼24 hours). After incubation with LPS,
supernatants were collected and immediately frozen at
−70◦C. The IL-1β and TNF-α levels of the supernatants were
measured using ELISA kits according to the manufacturer’s
protocol.
2.6. Western Blot Analysis. For determination of the expres-
sion of MAPKs in microglia, Western blot analyses were
performed as described previously [18]. Microglia (5 × 105
cells mL
−1) were cultured on 24-well plates and treated
with ketamine (100 and 250μM) or an isovolumetric
PBS buﬀer for 30 minutes followed by the addition of
LPS (100ngmL
−1). At indicated times, cells were washed
with ice-cold PBS buﬀer (pH 7.3). Proteins were extracted
with lysis buﬀer for 30 minutes. In addition, phosphatase
inhibitors (10mM sodium ﬂuoride, 1mM sodium ortho-
vanadate, and 10mM sodium pyrophosphate) were added
to the lysis buﬀer for the phosphorylated MAPK analysis.
Lysates were centrifuged, and the supernatant (50μgp r o -
tein) was subjected to SDS-PAGE and electrophoreticallyMediators of Inﬂammation 3
transferred onto PVDF membranes (0.45mm; Hybond-P;
Amersham). After incubation in blocking buﬀer (50mM
Tris-HCl, 100mMNaCl, 0.1% Tween 20, and 5% dry
skim milk; pH 7.5) overnight at 48 hours and being
washed three times with PBS buﬀer, blots were treated with
either anti-phospho-ERK1/2 (p42/44), anti-ERK1/2, anti-
phospho-JNK1/2 (p46/54), anti-JNK1/2, anti-p38 MAPK, or
anti-phospho-p38 MAPK mAbs (1:2000) in a PBS buﬀer
for 3 hours. They were subsequently washed three times
with PBS buﬀer and incubated with a peroxidase-conjugated
goat anti-mouse or anti-rabbit antibody (1:3000) for 2
hours. Blots were then washed three times, and the band
with peroxidase activity was detected using ﬁlm exposure
with enhanced chemiluminescence detection reagents (ECL+
system;Amersham).Densitometricanalysisofspeciﬁcbands
was performed using a Photo-Print Digital Imaging Sys-
tem (IP-008-SD) with analytic software (Bio-1Dlight, Vers.
2000).
2.7. Statistical Analysis. The experimental results are
expressed as the means ± S.E.M. and are accompanied by the
number of observations. Data were assessed by the method
of analysis of variance (ANOVA). If a signiﬁcant diﬀerence
among the group means was noted, the diﬀerence between
two groups would be assessed using the Newman-Keuls
method. A P value of <.05 was considered statistically
signiﬁcant.
3. Results
According to a preliminary test, activation of microglia
by LPS (100ngmL
−1) induced a signiﬁcant and marked
increase in nitrite formation. Therefore, an LPS concentra-
tion of 100ngmL
−1 was employed in the following experi-
ments. In this study, the concentration of nitrite produced in
the cell supernatant time-dependently increased from 0.5 ±
0.0 (resting) to 6.7 ± 0.3μM at 24 hours after LPS treat-
ment (Figure 1). Ketamine (100 and 250μM) concentration-
dependently inhibited LPS-(100ngmL
−1) stimulated nitrite
production by approximately 40% and 60%, respectively,
(Figure 1). Ketamine neither interfered with the Griess
reactionnor reactedwithnative NO(datanot shown).These
results demonstrate that ketamine markedly suppressed
NO production stimulated by LPS in microglia. Further-
more, neither ketamine (100∼500μM) (Figure 2)n o rL P S
(100ngmL
−1)(datanotshown)signiﬁcantlyaﬀectedthecell
viability of microglia for 24 hours according to the MTT
assay.
LPS (100ngmL
−1) induced a time-dependent increase
in IL-1β formation in microglia, and it reached a max-
imal level at 12 hours rising from 135.9 ± 6.5 (resting)
to 575.9 ± 10.6pgmL
−1 (Figure 3). On the other hand,
after pretreatment of cells with various concentrations of
ketamine for 30 minutes followed by the addition of LPS
(100ngmL
−1) for 12 hours, we found that ketamine (100
and 250μM) concentration-dependently inhibited IL-1β
production by approximately 13% and 36%, respectively,
(Figure 3).
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Figure 1: Eﬀect of ketamine on nitrite formation in LPS-activated
microglia.Microglia(5×105 cellsmL
−1)weretreatedwithketamine
(100 and 250μM) or an isovolumetric PBS buﬀer for 30 minutes,
followed by the addition of LPS (100ngmL
−1) for 24 hours. Cell-
free supernatants were assayed for nitrite production as described
in Section 2. Data are presented as the means ± S.E.M. (n = 3).
∗∗P<. 01, compared to the resting group; ##P<. 01, compared to
the PBS-treated group.
0
20
40
60
80
100
120
V
i
a
b
i
l
i
t
y
o
f
r
e
s
t
i
n
g
g
r
o
u
p
(
%
)
Resting PBS 100 200 350 500
Ketamine
Figure 2: Tetrazolium dye 3-(4, 5-dimethylthiazol-2-yl)-2,5-
diphenyl tetrazolium bromide (MTT) assay of ketamine-treated
microglia. Microglia (5 × 105 cells mL
−1) were treated with various
concentrations of ketamine (100∼500μM) or an isovolumetric
PBS buﬀer for 24 hours. Cell viability was measured by a
colorimetric assay at 550nm based on the ability of mitochondria
to reduce the MTT in viable cells. Data are presented as the means
± S.E.M. (n = 3).
On the other hand, activation of microglia by LPS
(100ngmL
−1) induced a signiﬁcant increase in TNF-α for-
mation. The peak activation of TNF-α f o r m a t i o no c c u r r e d3
hours after LPS (100ngmL
−1) stimulation (resting, 1042.2±
8.8pgmL
−1; 3 hours, 1992.8 ± 38.2pgmL
−1, n = 3)
(Figure 4). After pretreating cells with various concentra-
tions of ketamine for 30 minutes followed by the addition4 Mediators of Inﬂammation
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Figure 3: Eﬀect of ketamine on interleukin (IL)-1β production in
lipopolysaccharide (LPS)-activated microglia. Microglia (5 × 105
cells mL
−1) were treated with ketamine (100 and 250μM) or an
isovolumetricPBSbuﬀerfor30minutes,followedbytheadditionof
LPS(100ngmL
−1)for12hours.Cell-freesupernatantswereassayed
for IL-1β production as described in Section 2. Data are presented
as the means ± S.E.M. (n = 3). ∗∗P<. 01, compared to the resting
group; #P<. 05 and ##P<. 01, compared to the PBS-treated group.
of LPS (100ngmL
−1) for 3 hours, only ketamine at the
higherconcentration(500μM)signiﬁcantlyinhibitedTNF-α
production by approximately 11% (Figure 4).
To further investigate the inhibitory mechanisms of
ketamine in LPS-induced microglial activation, three
major MAPK signaling molecules were detected: ERK1/2,
JNK1/2, and p38 MAPK. The immunoblot analysis revealed
that treatment with LPS (100ngmL
−1) induced rapid
and marked time-dependent phosphorylation of ERK1/2
(p42/p44), JNK1/2 (p46/p54), and p38 MAPK, which
reached maximal levels at approximately 45 minutes and
then returned to the basal level (data not shown). After being
pretreated with ketamine (100 and 250μM) for 30 minutes,
phosphorylated ERK1/2 stimulated by LPS (100ngmL
−1)
was markedly inhibited by ketamine in a concentration-
dependent manner (Figure 5). However, neither JNK1/2
(Figure 6)n o rp 3 8M A P K( Figure 7) phosphorylation stim-
ulated by LPS was signiﬁcantly inhibited by ketamine (100
and 250μM).
4. Discussion
In this study, we demonstrate an anti-inﬂammatory eﬀect of
ketamine in primary cultured microglia. Ketamine exhibited
more potent activity at inhibiting both NO and IL-1β
formation than TNF-α in LPS-stimulated microglia. This
discrepancy, however, needs to be further investigated.
The high concentration (500μM) of ketamine caused no
signiﬁcant changes in the number of viable cells esti-
mated by the MTT reduction assay (Figure 2). This ﬁnding
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Figure 4:Eﬀectofketamineontumornecrosisfactor(TNF)-αpro-
duction in lipopolysaccharide (LPS)-activated microglia. Microglia
(5 × 105 cells mL
−1)w e r et r e a t e dw i t hv a r i o u sc o n c e n t r a t i o n so f
ketamine (100, 250, and 500μM) or an isovolumetric PBS buﬀer
for 30 minutes, followed by the addition of LPS (100ngmL
−1)f o r
3 hours. Cell-free supernatants were assayed for TNF-α production
as described in Section 2. Data are presented as the means ± S.E.M.
(n = 3). ∗∗P<. 01, compared to the resting group; #P<. 05,
compared to the PBS-treated group.
excluded the possibility that the release of the inﬂamma-
tory mediators was inhibited by the cytotoxic actions of
ketamine.
It is known that microglia play a key role in mediating
inﬂammatory processes in the CNS, which are associated
with various neurodegenerative diseases. LPS, a glycolipid
derived from the membrane surface of gram-negative bac-
teria (i.e., an endotoxin), can trigger a series of inﬂammatory
reactions in phagocytes such as microglia. With LPS stim-
ulation, microglia are activated to drastically change their
cellular functions, producing various types of inﬂammatory
mediators such as NO, TNF-α,a n dI L - 1 β.N Oa n dT N F -
α are two major inﬂammatory mediators. NO is beneﬁcial
as a messenger or modulator, but in conditions such as
oxidative stress, it is potentially toxic. NO generation by
activated microglia has been shown to cause excitotoxicity
through inducing glutamate release and inhibiting neuronal
respiration [20]. TNF-α and IL-1β released from activated
microgliaalsostimulateNOproductioninglialcellsandmay
have a direct eﬀect on neurons through activating receptors
that contain the death domains involved in apoptosis [21].
In general, total plasma levels of ketamine are reported
to be in the range of 33∼94μM immediately after
2.0∼2.2mgkg−1 i.v. administration in humans [22]. There-
fore, we considered 100μM to be a higher clinically relevant
concentration achievable during induction of ketamine
anesthesia, assuming that protein binding is comparable in
serum-supplemented media and plasma. Our studies suggest
that ketamine may modulate some of the inﬂammatory
responses (i.e., NO and IL-1β) of microglia stimulatedMediators of Inﬂammation 5
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Figure 5: Eﬀect of ketamine on ERK1/2 phosphorylation in
lipopolysaccharide (LPS)-activated microglia. Microglia (5 × 105
cells mL
−1) were treated with ketamine (100 and 250μM) or an
isovolumetric PBS buﬀer for 30 minutes, followed by the addition
of LPS (100ngmL
−1) for 45 minutes. ERK1/2 phosphorylation
was determined by Western blotting with a monoclonal antibody
which recognizes only phosphorylated ERK1/2 (p42/p44). Data are
presented as the means ± S.E.M. (n = 3). ∗∗P<. 01, compared to
the resting group; #P<. 05, compared to the PBS-treated group.
by LPS in vitro at the high range of clinically achievable
concentrations.
This anti-inﬂammatory property of ketamine may have
advantages in clinical therapy. An adequate inﬂammatory
reaction results from the equilibrium between proinﬂam-
matory and anti-inﬂammatory inﬂuences. Ketamine admin-
istrated in a stress situation favors this equilibrium. This
is based on clinical data published several years ago. The
survival rate in intensive care unit of patients with septic
shock was improved when they received ketamine as a
sedative [23].
MAPKs play important roles in mediating cytokine (i.e.,
TNF-α and IL-1β) release with LPS-stimulated microglial
activation [10, 11, 24]. We thus further investigated the
roles of MAPKs involved in ketamine-mediated suppression
of inﬂammatory responses in LPS-stimulated microglia.
MAPKs are a family of serine-threonine kinases activated
by many stimuli including growth factors and hormones
in proliferative cells [25]. MAPKs are able to regulate a
number of transcription factors, cytoplasmic proteins, and
downstream kinases. This family consists of three major
subgroups. ERK1/2 are involved in proliferation, adhesion,
and cell progression [25]. p38 MAPK and JNK1/2 or stress-
activated protein kinases, which include the 46-kDa JNK1
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Figure 6: Eﬀect of ketamine on JNK1/2 phosphorylation in
lipopolysaccharide (LPS)-activated microglia. Microglia (5 × 105
cells mL
−1) were treated with ketamine (100 and 250μM) or an
isovolumetric PBS buﬀer for 30 minutes, followed by the addition
of LPS (100ngmL
−1) for 45 minutes. JNK1/2 phosphorylation
was determined by Western blotting with a monoclonal antibody
which recognizes only phosphorylated JNK1/2 (p46/p54). Data are
presented as the means ± S.E.M. (n = 3). ∗∗P<. 01, compared to
the resting group.
and 54-kDa JNK2 isoforms, are involved in death signaling
processes [25]. In the present study, we found that ketamine
inhibited ERK1/2 but not JNK1/2 or p38 MAPK phos-
phorylation in LPS-stimulated microglia. Zhang et al. [26]
have reported that ketamine could abolish hyperglycemia-
activated ERK1/2 phosphorylation through inhibition of the
N-methyl D-aspartate-mediated calcium inﬂux, which sub-
sequently reduces the hyperglycemia-exaggerated damage
[26].
In conclusion, although ketamine has been shown to
exert anti-inﬂammatory eﬀects on a variety of immune cells,
the exact mechanisms responsible for these actions are not
well understood. Our results suggest that ketamine’s anti-
inﬂammatory activity may be mediated, at least in part,
by inhibition of ERK1/2 phosphorylation in primary cul-
tured microglia. However, more detailed anti-inﬂammatory
mechanisms of ketamine in microglia need to be further
investigated and classiﬁed.
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